AA
RVMD icon

ALPS Advisors’s Revolution Medicines RVMD Stock Holding History

ALPS Advisors’s Portfolio RVMD Stock Details RVMD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		– Sell
-116,156
Closed -$3.74M – 994
2024
Q1 		$3.74M Buy
116,156
+4,952
+4% +$147K 0.03% 268
2023
Q4 		$3.19M Buy
+111,204
New +$2.67M 0.03% 277

Other funds holding RVMD

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
NI
Nextech Invest Zurich, Switzerland $1.42B AUM 304.47% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
AI
Alphabet Inc Mountain View, California $4.02B AUM 215.74% 1-Year Est. Return
PBA
Paradigm Biocapital Advisors New York $4.89B AUM 251.12% 1-Year Est. Return

ALPS Advisors's RVMD Position: Q2 2024 in Review

ALPS Advisors sold out of Revolution Medicines (RVMD) in Q2 2024, closing a stake of 116,156 shares — an estimated $3.74M sold.

ALPS Advisors first reported a position in RVMD in Q4 2023 and held it in 2 quarters. The position peaked at $3.74M in Q1 2024. 223 funds tracked by Wall St. Rank hold RVMD as of Q2 2024.

  • ALPS Advisors reported no remaining Revolution Medicines position as of Q2 2024 after selling out during the quarter.
  • ALPS Advisors sold 116,156 Revolution Medicines shares in Q2 2024, an estimated $3.74M.
  • ALPS Advisors first reported a position in Revolution Medicines in Q4 2023 and held it in 2 quarters.
  • ALPS Advisors's Revolution Medicines position peaked at $3.74M in Q1 2024.
  • 223 funds tracked by Wall St. Rank held Revolution Medicines as of Q2 2024.

Based on ALPS Advisors's 13F filing for Q2 2024, filed 13 Aug 2024.